IP Library Granted Patent US 8,492,401
Granted Patent B2
US 8,492,401 · App. 13/678,292 · Granted Jul 23, 2013

Thiazolopyridine sirtuin modulating compounds

Inventors: Christopher Oalmann (Cambridge, MA); Jeremy S Disch (Cambridge, MA); Pui Yee Ng (Cambridge, MA); Robert B Perni (Cambridge, MA)
Assignee: GlaxoSmithKline LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,492,401
App. No.
13/678,292
Granted
Jul 23, 2013
Kind
B2
Abstract

Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Claims (21)

1. A pharmaceutical composition for topical administration comprising a compound represented by the structural formula:

or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable topical carrier.

2. The pharmaceutical composition for topical administration of claim 1 , comprising 0.001 to 10% by weight of the compound.

3. The pharmaceutical composition for topical administration of claim 2 , comprising 0.1 to 5% by weight of the compound.

4. The pharmaceutical composition for topical administration of claim 1 , comprising 0.25 to 75% by weight of the compound.

5. The pharmaceutical composition for topical administration of claim 4 , comprising 0.25 to 30% by weight of the compound.

6. The pharmaceutical composition for topical administration of claim 5 , comprising 0.25 to 15% by weight of the compound.

7. The pharmaceutical composition for topical administration of claim 6 , comprising 1.0 to 10% by weight of the compound.

8. The pharmaceutical composition for topical administration of claim 1 , wherein the topical carrier is selected from water, alcohol, glycerin, mineral oil, silicone, petroleum jelly, lanolin, fatty acids, vegetable oil, paraben, and wax.

9. The pharmaceutical composition for topical administration of claim 1 , wherein the composition is in a form selected from an ointment, a lotion, a cream, a microemulsion, a gel, an oil, and a solution.

10. The pharmaceutical composition for topical administration of claim 9 , wherein the composition is an ointment comprising petrolatum or another petroleum derivative.

11. The pharmaceutical composition for topical administration of claim 9 , wherein the composition is a lotion comprising a water or alcohol base.

12. The pharmaceutical composition for topical administration of claim 9 , wherein the composition is a cream comprising an oil phase, an emulsifier, and an aqueous phase.

13. The composition of claim 12 , wherein the oil phase is comprised of petrolatum and a fatty alcohol selected from cetyl and stearyl alcohol.

14. The composition of claim 12 , wherein the emulsifier is selected from a nonionic surfactant, an anionic surfactant, a cationic surfactant and an amphoteric surfactant.

15. The pharmaceutical composition for topical administration of claim 9 , wherein the composition is a microemulsion.

16. The pharmaceutical composition for topical administration of claim 9 , wherein the composition is a gel.

17. The pharmaceutical composition for topical administration of claim 11 , further comprising an additional active agent selected from an anti-inflammatory agent, an analgesic agent, an antimicrobial agent, an antifungal agent, an antibiotic agent, a vitamin, an antioxidant agent, and a sunblock agent.

18. A method of treating a skin disorder or disease associated with or caused by inflammation, sun damage, or natural aging comprising administering the pharmaceutical composition for topical administration of claim 1 to the skin or mucosal tissue of a subject in need thereof.

19. The method of claim 18 , wherein the skin disorder or disease is selected from contact dermatitis, allergic eczema, actinic keratosis, eczema, pemphigus, exfoliative dermatitis, seborrheic dermatitis, erythema multiforme, erythema nodosum, sun damage, discoid lupus erythematosus, dermatomyositis, psoriasis, skin cancer, and the effects of natural aging.

20. A method of treating a wound or a burn comprising administering the pharmaceutical composition for topical administration of claim 1 to the skin or mucosal tissue of a subject in need thereof.

Assignments (2)
MERGER Recorded Jun 24, 2013
From: SIRTRIS PHARMACEUTICALS, INC.
To: GLAXOSMITHKLINE LLC
Reel/Frame 030670/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2013
From: OALMANN, CHRISTOPHER; DISCH, JEREMY S.; NG, PUI YEE; PERNI, ROBERT B.
To: SIRTRIS PHARMACEUTICALS, INC.
Reel/Frame 029830/0975 →
Continuity (3)
Continuation 13139796
Provisional Application 61203156 · Dec 19, 2008
Related Publication 20130085155A1 · Apr 4, 2013